Acurx pharmaceuticals announces successful completion and early discontinuation of the ibezapolstat phase 2b trial for treatment of c. difficile infection

Based on observed aggregate blinded data the company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as expected high rates of clinical cure were observed without any emerging safety concerns data will be analyzed and topline efficacy results will be reported as soon as possible this successful milestone will allow advancement of this first-in-class, fda qidp/fast track-designated antibiotic candidate to phase 3 clinical trials more expeditiously staten island, n.y. , oct. 2, 2023 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the company has discontinued the phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for the treatment of patients with clostridioides difficile infection (cdi) due to success.
ACXP Ratings Summary
ACXP Quant Ranking